Emerging Diseases in Tropical Dermatology

Advances in Dermatology

Volumn 23, Issue , 2007, Pages 335-350

  High, Whitney A ^a   Bravo, Francisco G ^b  

^a UNIVERSITY OF COLORADO   (United States)

^b UNIVERSIDAD PERUANA CAYETANO HEREDIA   (Peru)

Author keywords

[No Author keywords available]

Indexed keywords

ADOLESCENT; AMEBIASIS; AMOEBA; ANIMAL; CHILD; COMMUNICABLE DISEASE; CUTANEOUS T CELL LYMPHOMA; HUMAN; ISOLATION AND PURIFICATION; MALE; MICROBIOLOGY; NEMATODIASIS; PATHOLOGY; PENICILLIUM; PYTHIUM; REVIEW; SKIN INFECTION; THELAZIA; VIRUS INFECTION;

ADOLESCENT; AMEBIASIS; AMOEBA; ANIMALS; CHILD; COMMUNICABLE DISEASES, EMERGING; EPSTEIN-BARR VIRUS INFECTIONS; GNATHOSTOMA; HUMANS; LYMPHOMA, T-CELL, CUTANEOUS; MALE; PENICILLIUM; PYTHIUM; SKIN DISEASES, INFECTIOUS; SPIRURIDA INFECTIONS;

EID: 36148973568     PISSN: 08820880     EISSN: None     Source Type: Book Series    
DOI: 10.1016/j.yadr.2007.07.008     Document Type: Review

References (77)

1. Visvesvara G.S., Martinez A., Schuster F.L., et al. Leptomyxid ameba, a new agent of amebic meningoencephalitis in humans and animals. J Clin Microbiol 28 (1990) 2750-2756
2. Tavares M., Correia da Costa J.M., Carpenter S.S., et al. Diagnosis of first case of Balamuthia amoebic encephalitis in Portugal by immunofluorescence and PCR. J Clin Microbiol 44 (2006) 2660-2663
3. Dunnebacke T.H., Schuster F.L., Yagi S., et al. Balamuthia mandrillaris from soil samples. Microbiology 150 (2004) 2837-2842
4. Schuster F.L., Glaser C., Honarmand S., et al. Balamuthia amebic encephalitis risk, Hispanic Americans. Emerg Infect Dis 10 (2004) 1510-1512
5. Chappell C.L., Wright J.A., Coletta M., et al. Standardized method of measuring acanthamoeba antibodies in sera from healthy human subjects. Clin Diagn Lab Immunol 8 (2001) 724-730
6. Recavarren-Arce S., Velarde C., Gotuzzo E., et al. Amoeba angeitic lesions of the central nervous system in Balamuthia mandrilaris amoebiasis. Hum Pathol 30 (1999) 269-273
7. Campos P., Cabrera J., Gotuzzo E., et al. Neurological involvement in free living amebiasis. Rev Neurol 29 (1999) 316-318
8. Bravo F., and Sanchez M.R. New and re-emerging cutaneous infectious diseases in Latin America and other geographic areas. Dermatol Clin 21 (2003) 655-668
9. Valverde J., Arrese J.E., and Pierard G.E. Granulomatous cutaneous centrofacial and mengocerebral amebiasis. Am J Clin Dermatol 7 (2006) 267-269
10. Deetz T.R., Sawyer M.H., Billman G., et al. Successful treatment of Balamuthia amoebic encephalitis: presentation of 2 cases. Clin Infect Dis 37 (2003) 1304-1312
11. Schuster F.L., and Visvesvara G.S. Efficacy of novel antimicrobials against clinical isolates of opportunistic amebas. J Eukaryot Microbiol 45 (1998) 612-618
12. Ollague W., Ollague J., Guevara A., et al. Human gnathostomiasis in Ecuador. First finding of the parasite in South America. Int J Dermatol 23 (1984) 647-651
13. Ogata K., Nawa Y., Akahane H., et al. Short report: gnathostomiasis in Mexico. Am J Trop Med Hyg 58 (1998) 316-318
14. Costa H., Bravo F., Valdez L., et al. Panniculitis migratoria eosinofilica en el Peru (Gnathostomiasis humana). Folia Dermatologica Peruana 12 (2001) 21-35
15. Moore D.A., McCroddan J., Dekumyoy P., et al. Gnathostomiasis: an emerging imported disease. Emerg Infect Dis 9 (2003) 647-650
16. Rusnak J.M., and Lucey D.R. Clinical gnathostomiasis: case report and review of the English-language literature. Clin Infect Dis 16 (1993) 33-50
17. Ratanarapee S., and Jesadapatarakul S. A case of gnathostomiasis simulating acute appendicitis. J Med Assoc Thai 65 (1982) 443-447
18. Schmidt G., and Roberts L. Foundations in parasitology (1985), Times Mirror/Mosby College Publishing, St. Louis (MO)
19. Schmutzhard E., Boongird P., and Vejjajiva A. Eosinophilic meningitis and radiculomyelitis in Thailand, caused by CNS invasion of Gnathostoma spinigerum and Angiostrongylus cantonensis. J Neurol Neurosurg Psychiatry 51 (1988) 80-87
20. Suntharasamai P., Riganti M., Chittamas S., et al. Albendazole stimulates outward migration of Gnathostoma spinigerum to the dermis in man. Southeast Asian J Trop Med Public Health 23 (1992) 716-722
21. Diaz Camacho S.P., Zazueta Ramos M., Ponce Torrecillas E., et al. Clinical manifestations and immunodiagnosis of gnathostomiasis in Culiacan, Mexico. Am J Trop Med Hyg 59 (1998) 908-915
22. Slevogt H., Grobusch M.P., and Suttorp N. Gnathostomiasis without eosinophilia led to a 5-year delay in diagnosis. J Travel Med 10 (2003) 196
23. Anantaphruti M.T., Nuamtanong S., and Dekumyoy P. Diagnostic values of IgG4 in human gnathostomiasis. Trop Med Int Health 10 (2005) 1013-1021
24. Nontasut P., Bussaratid V., Chullawichit S., et al. Comparison of ivermectin and albendazole treatment for gnathostomiasis. Southeast Asian J Trop Med Public Health 31 (2000) 374-377
25. Nontasut P., Claesson B.A., Dekumyoy P., et al. Double-dose ivermectin vs albendazole for the treatment of gnathostomiasis. Southeast Asian J Trop Med Public Health 36 (2005) 650-652
26. Wiwanitkit V. A review of human sparganosis in Thailand. Int J Infect Dis 9 (2005) 312-316
27. Supparatpinyo K., Khamwan C., Baosoung V., et al. Disseminated Penicillium marneffei infection in southeast Asia. Lancet 344 (1994) 110-113
28. Sirisanthana T., and Supparatpinyo K. Epidemiology and management of penicilliosis in human immunodeficiency virus-infected patients. Int J Infect Dis 3 (1998) 48-53
29. Supparatpinyo K., and Sirisanthana T. New fungal infections in the Western Pacific. JAMA Southeast Asia 10 Supp 3 (1994) 208-209
30. Deng Z.L., Yun M., and Ajello L. Human penicilliosis marneffei and its relation to the bamboo rat. J Med Vet Mycol 24 (1986) 383-389
31. Filiotou A., Velegraki A., Giannaris M., et al. First case of Penicillium marneffei fungemia in Greece and strain susceptibility to five licensed systemic antifungal agents and posaconazole. Am J Med Sci 332 (2006) 43-45
32. Sobottka I., Albrecht H., Mack D., et al. Systemic Penicillium marneffei infection in a German AIDS patient. Eur J Clin Microbiol Infect Dis 15 (1996) 256-259
33. Sekhon A.S., Stein L., Garg A.K., et al. Pulmonary penicillosis marneffei: report of the first imported case in Canada. Mycopathologia 128 (1994) 3-7
34. Ungpakorn R. Cutaneous manifestations of Penicillium marneffei infection. Curr Opin Infect Dis 13 (2000) 129-134
35. Kaufman L., Standard P.G., Anderson S.A., et al. Development of specific fluorescent-antibody test for tissue form of Penicillium marneffei. J Clin Microbiol 33 (1995) 2136-2138
36. Tsunemi Y., Takahashi T., and Tamaki T. Penicillium marneffei infection diagnosed by polymerase chain reaction from the skin specimen. J Am Acad Dermatol 49 (2003) 344-346
37. Prariyachatigul C., Chaiprasert A., Geenkajorn K., et al. Development and evaluation of a one-tube seminested PCR assay for the detection and identification of Penicillium marneffei. Mycoses 46 (2003) 447-454
38. Duong T.A. Infection due to Penicillium marneffei, an emerging pathogen: review of 155 reported cases. Clin Infect Dis 23 (1996) 125-130
39. Wong S.S., Wong K.H., Hui W.T., et al. Differences in clinical and laboratory diagnostic characteristics of penicilliosis marneffei in human immunodeficiency virus (HIV)- and non-HIV-infected patients. J Clin Microbiol 39 (2001) 4535-4540
40. Drouhet E. Penicilliosis due to Penicillium marneffei: a new emerging systemic mycosis in AIDS patients traveling or living in Southeast Asia. J Mycol Med 4 (1993) 195-224
41. Supparatpinyo K., Chiewchanvit S., Hirunsri P., et al. An efficacy study of itraconazole in the treatment of Penicillium marneffei infection. J Med Assoc Thai 75 (1992) 688-691
42. Supparatpinyo K., Nelson K.E., Merz W.G., et al. Response to antifungal therapy by human immunodeficiency virus-infected patients with disseminated Penicillium marneffei infections and in vitro susceptibilities of isolates from clinical specimens. Antimicrob Agents Chemother 37 (1993) 2407-2411
43. Pfaller M.A., Messer S.A., Hollis R.J., et al. Antifungal activities of posaconazole, ravuconazole, and voriconazole compared to those of itraconazole and amphotericin B against 239 clinical isolates of Aspergillus spp. and other filamentous fungi. Antimicrob Agents Chemother 46 (2002) 1032-1037
44. Supparatpinyo K., Perriens J., Nelson K.E., et al. A controlled trial of itraconazole to prevent relapse of Penicillium marneffei infection in patients infected with the human immunodeficiency virus. N Engl J Med 339 (1998) 1739-1743
45. Chariyalertsak S., Supparatpinyo K., Sirisanthana T., et al. A controlled trial of itraconazole as primary prophylaxis for systemic fungal infections in patients with advanced human immunodeficiency virus infection in Thailand. Clin Infect Dis 34 (2002) 277-284
46. De Cock A.W., Mendoza L., Padhye A.A., et al. Pythium insidiosum sp. nov., the etiologic agent of pythiosis. J Clin Microbiol 25 (1987) 344-349
47. Mendoza L. Pythium insidiosum. In: Ajello L., and Hay R.J. (Eds). Topley and Wilson's microbiology and microbial infections. vol. 4, Mycology (2000), Arnold, London 487-496
48. Bosco Sde M., Bagagli E., Araujo Jr. J.P., et al. Human pythiosis, Brazil. Emerg Infect Dis 11 (2005) 715-718
49. Rivierre C., Laprie C., Guiard-Marigny O., et al. Pythiosis in Africa. Emerg Infect Dis 11 (2005) 479-481
50. Mendoza L., Hernandez F., and Ajello L. Life cycle of the human and animal oomycete pathogen Pythium insidiosum. J Clin Microbiol 31 (1993) 2967-2973
51. Ravishankar J.P., Davis C.M., Davis D.J., et al. Mechanics of solid tissue invasion by the mammalian pathogen Pythium insidiosum. Fungal Genet Biol 34 (2001) 167-175
52. Krajaejun T., Sathapatayavongs B., Pracharktam R., et al. Clinical and epidemiological analyses of human pythiosis in Thailand. Clin Infect Dis 43 (2006) 569-576
53. Mendoza L., and Prendas J. A method to obtain rapid zoosporogenesis of Pythium insidiosum. Mycopathologia 104 (1988) 59-62
54. Chaiprasert A., Samerpitak S., Wanachiwanawin W., et al. Induction of zoospore formation in Thai isolates of Pythium insidiosum. Mycoses 33 (1990) 317-323
55. Pracharktam R., Changtrakool P., Sathapatayavongs B., et al. Immunodiffusion test for diagnosis and monitoring of human pythiosis insidiosi. J Clin Microbiol 29 (1991) 2661-2662
56. Imwidthaya P., and Srimuang S. Immunodiffusion test for diagnosing human pythiosis. Mycopathologia 106 (1989) 109-112
57. Krajaejun T., Kunakorn M., Niemhom S., et al. Development and evaluation of an in-house enzyme-linked immunosorbent assay for early diagnosis and monitoring of human pythiosis. Clin Diagn Lab Immunol 9 (2002) 378-382
58. Mendoza L., Kaufman L., and Standard P. Antigenic relationship between the animal and human pathogen Pythium insidiosum and nonpathogenic Pythium species. J Clin Microbiol 25 (1987) 2159-2162
59. Brown C.C., McClure J.J., Triche P., et al. Use of immunohistochemical methods for diagnosis of equine pythiosis. Am J Vet Res 49 (1988) 1866-1868
60. Vanittanakom N., Supabandhu J., Khamwan C., et al. Identification of emerging human-pathogenic Pythium insidiosum by serological and molecular assay-based methods. J Clin Microbiol 42 (2004) 3970-3974
61. Schlosser E., and Gottlieb D. Sterols and the sensitivity of Pythium species to filipin. J Bacteriol 91 (1966) 1080-1084
62. Triscott J.A., Weedon D., and Cabana E. Human subcutaneous pythiosis. J Cutan Pathol 20 (1993) 267-271
63. Shenep J.L., English B.K., Kaufman L., et al. Successful medical therapy for deeply invasive facial infection due to Pythium insidiosum in a child. Clin Infect Dis 27 (1998) 1388-1393
64. Kwon-Chung K.J. Phylogenetic spectrum of fungi that are pathogenic to humans. Clin Infect Dis 19 Suppl 1 (1994) S1-S7
65. Abuhammour W., and Habte-Gaber E. Newer antifungal agents. Indian J Pediatr 71 (2004) 253-259
66. Mendoza L., Mandy W., and Glass R. An improved Pythium insidiosum-vaccine formulation with enhanced immunotherapeutic properties in horses and dogs with pythiosis. Vaccine 21 (2003) 2797-2804
67. Kaufman L. Penicilliosis marneffei and pythiosis: emerging tropical diseases. Mycopathologia 143 (1998) 3-7
68. Gupta G., Man I., and Kemmett D. Hydroa vacciniforme: a clinical andy follow-up study of 17 cases. J Am Acad Dermatol 42 (2000) 208-213
69. Goldgeier M.H., Nordlund J.J., Lucky A.W., et al. Hydroa vaccineforme: diagnosis and therapy. Arch Dermatol 118 (1982) 588-591
70. Oono T., Arata J., Masuda T., et al. Coexistence of hydroa vacciniforme and malignant lymphoma. Arch Dermatol 122 (1986) 1306-1309
71. Asada H., Okada N., Tei H., et al. Epstein-Barr virus-associated large granular lymphocyte leukemia with cutaneous infiltration. J Am Acad Dermatol 31 (1994) 251-255
72. Cho K.H., Kim C.W., Lee D.Y., et al. Epstein-Barr virus-associated lymphoproliferative lesion of the skin presenting as recurrent necrotic papulovesicles of the face. Br J Dermatol 134 (1996) 791-796
73. Ruiz-Maldonado R., Parrilla F.M., Orozco-Covarrubias M.L., et al. Edematous, scarring vasculitic panniculitis. J Am Acad Dermatol 32 (1995) 37-44
74. Magana M., Sangueza P., Gil-Beristain J., et al. Angiocentric cutaneous T-cell lymphoma of childhood (hydroa-like lymphoma): a distinctive type of cutaneous T-cell lymphoma. J Am Acad Dermatol 38 (1998) 574-579
75. Barrionuevo C., Anderson V.M., Zevallos-Giampietri E., et al. Hydroa-like cutaneous T-cell lymphoma. Appl Immunohistochem Mol Morphol 10 (2002) 7-14
76. Iwatsuki K., Satoh M., Yamamoto T., et al. Pathogenic link between hydroa vacciniforme and Epstein-Barr virus-associated hematologic disorders. Arch Dermatol 142 (2006) 587-595
77. Willemze R., Jaffe E.S., Burg G., et al. WHO-EORTC classification for cutaneous lymphoma. Blood 105 (2005) 3768-3785